2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study
Yegya-Raman N, Plastaras J, Wright C, Chelius M, Zhang S, Baron J, Hubbeling H, Sim A, Robinson T, Jain M, Imber B, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix C, Gunther J, Fang P, Wu S, Dabaja B, Yang J, Chew J, Braunstein S, Sinha S, Delinger N, Sun S, Terezakis S, Sakthivel G, Constine L, Chowdhry A, Reagan P, Burke S, Tseng Y, LaRiviere M, Maity A, Schuster S, Chong E, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Advances 2025, 9: 3293-3303. PMID: 40203192, DOI: 10.1182/bloodadvances.2025015855.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeSuperior progression-free survivalProgression-free survivalB-cell lymphomaCytokine release syndromeAssociated with superior progression-free survivalOverall survivalTwo-year progression-free survivalChimeric antigen receptor T cellsLactate dehydrogenaseRelapsed/refractory B-cell lymphomaLactate dehydrogenase normalizationAmerican Society for TransplantationT-cell therapyBaseline lactate dehydrogenaseMedian Follow-UpRetrospectively reviewed patientsAdvanced-stage diseaseHigh-risk cohortAxicabtagene ciloleucelBrexucabtagene autoleucelSystemic therapyMulticenter studyT cellsNC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression.
Giridharan T, Suzuki S, Khan A, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz A, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons T, Yaffe M, Zsiros E, Dey P, McGray A, Segal B. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. The Journal Of Immunology 2025 PMID: 40560129, DOI: 10.1093/jimmun/vkaf121.Peer-Reviewed Original ResearchOvarian cancerLAIR-2Immune cellsOverall survivalTumor cellsAssociated with better OSAssociated with worse overall survivalHigh-grade serous ovarian cancerNon-small cell lung cancerSingle-center retrospective analysisTumor-infiltrating immune cellsT-cell suppressor functionLAIR-1Stromal immune cellsT-cell non-responsivenessEpithelial ovarian cancerT cell suppressionSerous ovarian cancerCell lung cancerImmune cell infiltrationT cell proliferationT cell membraneOptimal debulkingMalignant effusionsAdvanced OCArtificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
Fa'ak F, Coudray N, Jour G, Ibrahim M, Illa-Bochaca I, Qiu S, Claudio Quiros A, Yuan K, Johnson D, Rimm D, Weber J, Tsirigos A, Osman I. Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors. Clinical Cancer Research 2025 PMID: 40553453, DOI: 10.1158/1078-0432.ccr-24-3720.Peer-Reviewed Original ResearchResponse to ICIImmune checkpoint inhibitorsMetastatic melanoma cohortCheckpoint inhibitorsMelanoma cohortMelanoma treated with immune checkpoint inhibitorsBiomarkers of ICI responseImmune checkpoint inhibitor useImmune checkpoint inhibitor treatmentCohort of melanoma patientsLow tumor stroma ratioProgression-free survivalTumor-stroma ratioSignificant adverse eventsArea under the curvePatient overall survivalMetastatic settingUnresectable melanomaEpithelioid histologyICI responseMelanoma patientsMetastatic melanomaOverall survivalPatient survivalTumor featuresManagement of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline
Howington J, Souter L, Arenberg D, Blasberg J, Detterbeck F, Farjah F, Lanuti M, Leighl N, Videtic G, Murthy S. Management of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline. CHEST Journal 2025 PMID: 40562304, DOI: 10.1016/j.chest.2025.06.023.Peer-Reviewed Original ResearchStage I NSCLCNon-small cell lung cancerStereotactic body radiotherapyEpidermal growth factor receptorCell lung cancerOverall survivalLung cancerGrading of RecommendationsII NSCLCSurgical resectionEarly-stage non-small cell lung cancerLow operative risk patientsStage I lung cancerUsefulness of adjuvant chemotherapyPrimary treatment of patientsStage ITherapy improves overall survivalResected stage IBStage II NSCLCImproved overall survivalMutant lung cancerOperative risk patientsHilar lymph node samplingMinimally invasive approachTreatment of patientsIntegrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances In Hematology 2025, 16: 20406207251347344. PMID: 40546817, PMCID: PMC12182606, DOI: 10.1177/20406207251347344.Peer-Reviewed Original ResearchThis study investigates the immune landscape of RNA splicing factor-mutant AML and MDS, showing no survival benefit from adding durvalumab to azacitidine treatment.Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. ESMO Open 2025, 10: 105330. PMID: 40532362, PMCID: PMC12212133, DOI: 10.1016/j.esmoop.2025.105330.Peer-Reviewed Original ResearchMetastatic breast cancerHER2-positive diseaseTriple-negative diseaseT-DXdHER2-positiveOverall survivalTrastuzumab deruxtecanSacituzumab govitecanBreast cancerHR-positive/HER2-negative metastatic breast cancerHuman epidermal growth factor receptor 2 (HER2)-positiveElectronic health record-derived databaseHER2-negative metastatic breast cancerClinical trialsAssociated with inferior outcomesHormone receptorsTreat metastatic breast cancerHR-positive/HER2-negativeMedian prior linesProgression-free survivalKaplan-Meier methodDatabase of patientsLines of treatmentAntibody-drug conjugatesHER2-negativeLong-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.
Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'Malley B, Ozer E, Ikpeazu C, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. Journal Of Clinical Oncology 2025, jco2402550. PMID: 40493877, DOI: 10.1200/jco-24-02550.Peer-Reviewed Original ResearchExtranodal extensionOverall survivalOropharynx cancerTransoral surgeryRisk of late recurrenceLong-term follow-upFavorable pathologic characteristicsPhase II trialECOG-ACRINWeekly cisplatinN1 diseaseNeck dissectionProgression-FreeLate recurrenceNeck nodesArm AAdjuvant treatmentSmoking historyPostoperative managementPathological characteristicsPrimary sitePFSPatientsSurgeryCancerOver Two Decades of Experience in Aortic Arch Reoperations: Long-Term Outcomes and Mortality Risk Factors
Bozini N, Piber N, Vitanova K, Sideris K, Herold U, Guenzinger R, Amabile A, Georgescu T, Krane M, Prinzing A. Over Two Decades of Experience in Aortic Arch Reoperations: Long-Term Outcomes and Mortality Risk Factors. Journal Of Clinical Medicine 2025, 14: 4087. PMID: 40565833, PMCID: PMC12193799, DOI: 10.3390/jcm14124087.Peer-Reviewed Original ResearchAortic arch reoperationArch reoperationLong-term outcomesTemporary mechanical circulatory supportBleeding complicationsMechanical circulatory supportRisk factorsOverall survivalVentilation timeAdverse outcomesAssociated with significantly lower overall survivalSignificantly lower overall survivalAortic type B dissectionHistory of coronary artery diseaseMultivariate Cox regression analysisPredictor of adverse outcomesIncreased long-term survivalCirculatory supportAortic arch surgeryProlonged ventilation timeAssociated with high mortalityPreoperative risk factorsType B dissectionHigher mortalityTranscatheter aortic valve implantationLong-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer
Choi J, Sherman E, Dee E, Treechairusame T, Zakeri K, Kang J, Yu Y, Chen L, Shamseddine A, McBride S, Riaz N, Ho A, Tuttle R, Fagin J, Sabra M, Cracchiolo J, Shaha A, Wong R, Ghossein R, Katabi N, Lee N. Long-Term Results of External Beam Radiation Therapy with or Without Concurrent Chemotherapy in Differentiated Thyroid Cancer. Thyroid 2025, 35: 633-641. PMID: 40504742, DOI: 10.1089/thy.2025.0052.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsExternal beam radiation therapyBeam radiation therapyConcurrent chemotherapyRadiation therapyTracheoesophageal fistulaLocoregional controlPercutaneous endoscopic gastrostomyOverall survivalResults of external beam radiation therapyPatients treated with concurrent chemotherapyFollow-upTKI initiationTreated with concurrent chemotherapyTyrosine kinase inhibitor therapyRare group of patientsLong-term follow-upGross residual diseaseTreated with RTRadioactive iodine therapySingle-institution experienceDifferentiated thyroid cancerMedian Follow-UpKaplan-Meier methodDay of RTElevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
Mack P, Redman M, Tukachinsky H, Kozono D, Minichiello K, Dragnev K, Tolba K, Neal J, Madison R, Waqar S, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study. Clinical Cancer Research 2025 PMID: 40465842, DOI: 10.1158/1078-0432.ccr-24-3658.Peer-Reviewed Original ResearchCirculating tumor DNAPositive percent agreementOverall survivalTumor fractionAdvanced NSCLCMutation detectionAdvanced non-small cell lung cancerAssociated with significantly worse overall survivalMaximum somatic allele frequencyNon-small cell lung cancerSignificantly worse overall survivalTF levelsCopy number gainCell lung cancerPaired tumor tissuesPatient overall survivalVariant allele frequencyMutational concordanceTumor aneuploidyAllele frequenciesFoundation MedicineTumor DNAClinical outcomesPlasma levelsLung cancerPRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
Dragnev K, Redman M, Reckamp K, Khalil M, Henick B, Moon J, Ahmadzai P, LeBlanc M, Carrizosa D, Hesketh P, Sigal E, Allen J, Saltos A, Faller B, Herbst R, Blanke C, Gray J. PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2025, 43: lba8671-lba8671. DOI: 10.1200/jco.2025.43.17_suppl.lba8671.Peer-Reviewed Original ResearchSquamous cell carcinomaOverall survivalAdvanced NSCLCRecurrent non-small cell lung cancerRandomized phase III trialMedian of follow-upNon-small cell lung cancerPhase II Randomized StudyInterim analysisTreated with ICIPlatinum-based therapyTreated with immunotherapyPhase III trialsCell lung cancerLong follow-upStandard of careChemotherapy-freeHistological subgroupsNon-SCCIII trialsCell carcinomaMedian ageToxicity profileRandomized studyAdverse eventsORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Riess J, de Langen A, Ponce S, Goldberg S, Piotrowska Z, Goldman J, Le X, Cho B, Yoneshima Y, Ambrose H, Cavazzina R, Tang K, Lau J, Yu H. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precision Oncology 2025, 9: e2400818. PMID: 40466026, DOI: 10.1200/po-24-00818.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerLung cancerEpidermal growth factor receptor alterationsFirst-line osimertinibSafety of osimertinibProgression-free survivalDuration of responseNovel drug combinationsData cutoffPartial responseOsimertinib resistanceRisk-benefit analysisOverall survivalReceptor alterationsDiscontinued treatmentInvestigator assessmentClinical benefitNecitumumabSafety profileOsimertinibReport final resultsAdverse eventsDrug combinationsSmall Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Original ResearchThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsBreast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review
Mattia A, Alomari M, Hyjazie T, Devisetti N, Shen Y, Haykal S. Breast Reconstruction in De Novo Metastatic Breast Cancer: A Systematic Review. Plastic & Reconstructive Surgery Global Open 2025, 13: e6810. PMID: 40469550, PMCID: PMC12133142, DOI: 10.1097/gox.0000000000006810.Peer-Reviewed Original ResearchMetastatic breast cancerDnMBC patientsBreast reconstructionClinical outcomesBreast cancerHuman epidermal growth factor receptor 2-positiveEpidermal growth factor receptor 2-positiveBreast cancer-specific survival ratesDe novo metastatic breast cancerCancer-specific survival ratesSurvival rateSystematic reviewImplant-based reconstructionMetastasize to boneInvasive ductal carcinomaProlonged survival rateLow disease burdenOligometastatic diseasePreferred Reporting ItemsPrimary tumorOverall survivalDuctal carcinomaEstrogen-positiveSurgical candidatesSurgical detailsEpidemiology of Neuroendocrine Neoplasms in the US
Dasari A, Wallace K, Halperin D, Maxwell J, Kunz P, Singh S, Chasen B, Yao J. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open 2025, 8: e2515798. PMID: 40553474, PMCID: PMC12188367, DOI: 10.1001/jamanetworkopen.2025.15798.Peer-Reviewed Original ResearchConceptsDuration prevalenceIncidence rateNational Cancer Institute's SurveillanceNeuroendocrine neoplasmsOverall survivalNeuroendocrine tumorsAge-adjusted incidenceSurvival trends of patientsAnnual age-adjusted incidenceNeuroendocrine neoplasm casesCross-sectional studyHighest incidence ratePrimary siteTrends of patientsInstitute's SurveillanceMain OutcomesPrevalence of neuroendocrine neoplasmsSmall bowelPrimary site of originFactors associated with survivalDiagnosis of early stage diseasePractice patternsPancreatic neuroendocrine tumorsGastrointestinal neuroendocrine tumorsEarly stage diseaseLong-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study.
Medina T, Chesney J, Kluger H, Hamid O, Whitman E, Cusnir M, Thomas S, Wermke M, Domingo-Musibay E, Phan G, Kirkwood J, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik A, Curti B, Kim K, Daniels G, Wilson M, Lee S, Puzanov I, Harker-Murray A, Logan T, Simon J, Thomas I, Schuler-Thurner B, Moritz R, Hassel J, Grigoliet G, Arance A, Rubio B, Rodriguez J, Berrocal A, de Sanmamed M, Arkenau H, Evans T, Corrie P, Dalle S, Bedane C, Olah J, Orcurto A. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study. Journal Of Clinical Oncology 2025, 101200jco2500765. PMID: 40454684, DOI: 10.1200/jco-25-00765.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesOverall survivalLong-term efficacyCell therapyMedian duration of responseLow tumor burdenMedian overall survivalDuration of responseTumor burden reductionLong-term safety concernsBRAF/MEK inhibitorsAdvanced melanomaBrain metastasesImmune checkpointsTumor burdenMedian durationSafety profileAdverse eventsTreatment optionsInterleukin-2Follow-upLong-term benefitsOverall populationPatientsCutoff dateDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodComprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC).
Deshmukh S, Wu S, Xiu J, Hong C, Yao S, Sudmeier L, Kalinski P, Chalasani P, Repasky E, Ernstoff M, Leone J, Chumsri S, Graff S, Lustberg M, Sledge G, Kalinsky K, Gandhi S. Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1107-1107. DOI: 10.1200/jco.2025.43.16_suppl.1107.Peer-Reviewed Original ResearchTriple negative breast cancerBreast cancerOverall survivalTumor microenvironmentReal-world overall survivalADRB2 gene expressionNegative breast cancerImmune cell fractionsB2 adrenergic receptorPromote tumor growthMann-Whitney U testHighest survival benefitTriple negative breast cancer samplesKaplan-Meier estimatesSurvival benefitImmunological featuresGene expressionPreclinical modelsImmune characterizationTumor growthMann-WhitneyObservational studyU testADRB2RNA expressionEffect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer.
Hrinczenko B, Adeyelu T, Wei W, Elliott A, Bepler G, Vanderwalde A, Halmos B, Antonarakis E, Lustberg M, Jacob J. Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer. Journal Of Clinical Oncology 2025, 43: 2633-2633. DOI: 10.1200/jco.2025.43.16_suppl.2633.Peer-Reviewed Original ResearchNon-small cell lung cancerSmall cell lung cancerImmune checkpoint inhibitorsMetastatic non-small cell lung cancerProgression-free survivalCell lung cancerOverall survivalLung cancerLILRB4 expressionICI responsePrimary non-small cell lung cancerMetastatic small cell lung cancerSuppress adaptive immune responsesAssociated with improved survivalICI-treated patientsAssociated with OSImprove survival outcomesAdaptive immune responsesLung cancer typesDatasets of non-small cell lung cancerAnti-inflammatory pathwayLung cancer survivalAtezolizumab treatmentTSC22D3 expressionCheckpoint inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply